Warner-lambert Company

Other

Harriet W Hamilton

William Chester Patt

Annette M Doherty

Ila Sircar

Bharat Kalidas Trivedi

Walter H Moos

Joseph Thomas Repine

John C Hodges

Cleo Connolly

John Michael Domagala

Larry James Markoski

Edmund Lee Ellsworth

Bradley Dean Tait

Elizabeth Ann Lunney

Susan E Hagen

Frederick Earl Boyer

Christopher Andrew Gajda

David T Connor

Bruce D Roth

Alexander James Bridges

Michael Francis Rafferty

James S Kaltenbronn

Louis Brogley

Yuntao Song

Lain-Yen Hu

Thomas C Malone

Richard John Booth

Wayne Livingston Cody

Robert F Bruns

John Quin, Iii

Laszlo Nadasdi

John Xiaoqiang He

Balazs G Szoke

Edward W Badger

Laszlo Urge

Josyula Venkata Prasad

Robert P Steffen

Bruce Allan Steinbaugh

Diego F Silva

Josyula Venkata Vara Prasad

Deedee L Szotek

Leonard Joseph Lescosky

Peptidyl calcium channel blockers

This invention pertains to improved antiviral activity of 6,6-disubstituted-5,6-dihydropyran-2-ones caused by judicious placement of certain polar substituents at the 3 and/or 6 positions. The same substituents which enhance the cellular activity also diminish cytotoxicity further enhancing the desirable properties of these agents as antivirals.

Dihydropyrones with improved antiviral activity

The invention concerns novel renin-inhibitory compounds which contain an amino-substituted heterocycle at the P.sub.2 position. These are useful for treating renin-associated hypertension, congestive heart failure, glaucoma, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the compounds, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.

Amino-substituted heterocycles as renin inhibitors

Novel acylated amino acids which are antagonists of endothelin are described. Methods for their preparation and pharmaceutical compositions containing them are also included. The compounds are expected to be useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, myocardial ischemia, cerebral vasospasm, cirrhosis, septic shock, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, diabetes, head injury, and stroke.

Acylated amino acids as endothelin antagonists

The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism and diseases caused by retroviruses including HTLV-I and -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.

Renin inhibitors, processes for preparing them, methods for using them,

The invention concerns novel renin-inhibitory compounds which contain a tetrahydroisoquinoline or similar heterocycle at the P.sub.3 position. These are useful for treating hypertension, congestive heart failure, glaucoma, hyperaldosteronism, and diseases caused by retroviruses including HTLV-I, -II and -III. Processes for preparing the compounds, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, or hyperaldosteronism.

Tetrahydroisoquinoline-type renin inhibiting peptides

The invention concerns novel renin-inhibitory peptides which are useful for treating renin-associated hypertension, congestive heart failure, hyperaldosteronism, glaucoma, and diseases caused by retroviruses including HTLV-I, -II, -III. Processes for preparing the peptides, novel intermediates useful in the preparation thereof, compositions containing them, and methods of using them are included. Also included is a diagnostic method which uses the compounds to determine the presence of renin-associated hypertension, congestive heart failure, or hyperaldosteronism.

Bisalkoxyphosphinyl compounds as renin inhibitors

Novel substituted derivatives of 3-amino-2-hydroxypropionic acid are described, as well as methods for the preparation and pharmaceutical compositions of same, which are useful as renin inhibitors and thus useful in controlling hypertension, hyperaldosteronism and congestive heart failure as well as diagnostic agents.

Substituted derivatives of 3-amino-2-hydroxypropionic acid as inhibitors

Renin inhibitors, method for using them, and compositions containing them

Novel N.sup.6 -substituted-5'-oxidized adenosine analogs, and pharmaceutical compositions, methods of use or processes to make therefor. The novel adenosines have utility for the treatment of hypertension, coronary insufficiency, psychosis, pain, angina, and heart failure.

Method of treating psychosis using N.sup.6 -substituted -5'-oxidized

Novel N.sup.6 -substituted adenosines having desirable ratio of affinities at A1 or A2 receptors and highly desirable central nervous system and cardiovascular activities, such as analgesic, antipsychotic, sedative, or antihypertensive as well as immunoinflammatory activity.

2,N.sup.6 -disubstituted adenosines, derivatives and methods of use

Growing community of inventors

Chelsea, MI, United States of America

Harriet W Hamilton